Is US health care too broken to cure cancer?

The United States has directed billions of dollars toward cancer research over many years, yet the disease continues to be among the nation’s deadliest illnesses. That contrast between heavy investment and persistent mortality formed the backdrop for recent remarks by Ted Okon, who leads the Community Oncology Alliance. Okon told Al Jazeera’s program ‘This is America’ that a scientific cure alone would not resolve the larger problem: the U.S. health care system, as he described it, would still be unable to provide treatment for all people with cancer. His comment underscores a separation between discovering effective therapies and ensuring they reach every patient who needs them. The exchange raises questions about the capacity, financing and organization of cancer care in the United States. If a cure were developed but delivery systems, insurance coverage, provider availability or other aspects of the health system remained unchanged, many patients might still lack access to treatment. The discussion on Al Jazeera points to a broader policy debate: large research investments improve the prospects for medical breakthroughs, but their population-level benefits depend on whether the health system can equitably deliver those advances to everyone who needs them.